This trial is testing a drug to see if it can help treat myelofibrosis, a disease which causes problems with blood cell production.
- Primary Myelofibrosis
- Essential Thrombocythemia Myelofibrosis Transformation
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
1 Primary · 8 Secondary · Reporting Duration: Up to 5 years
Side Effects for
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Elotuzumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the scope of this clinical experiment in terms of participant numbers?
"Yes, clinicaltrials.gov evidences that this research is actively recruiting volunteers for a trial which was first made public on February 10th 2021 and most recently updated in November 11th 2022. The study requires 15 participants from 1 medical centre." - Anonymous Online Contributor
Is there capacity for more volunteers at this trial?
"According to the entry on clinicaltrials.gov, this medical trial is open to participants and has seen recent updates since its initiation back in February 2021. The most recent changes were posted on November 2022." - Anonymous Online Contributor
Has Elotuzumab been tested in other laboratory settings?
"Currently, there are 23 clinical trials being conducted with elotuzumab. Of these studies, 3 have reached phase III and 857 sites around the world are involved in their execution. The majority of locations for this research are located within Houston, Texas." - Anonymous Online Contributor
Could you provide an overview of Elotuzumab's safety profile?
"Elotuzumab's safety rating on a scale from 1-3 is 2 as this phase 2 trial has generated data supporting its security, yet efficacy remains unproven." - Anonymous Online Contributor